Phase 2 clinical trial of bi-weekly dosing of irofulven plus capecitabine in patients with anaplastic or locally advanced/metastatic differentiated thyroid cancer
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2009
At a glance
- Drugs Capecitabine; Irofulven
- Indications Thyroid cancer
- Focus Therapeutic Use
- 06 Nov 2008 'Eisai Medical Research' added as trial sponsor as reported by ClinicalTrials.gov.
- 27 Jan 2007 Status changed from recruiting to completed
- 13 Nov 2005 New trial record.